Experienced in Familial Wilms Tumor 2

Dr. Marvin J. Feldman

Hematology Oncology | Hematology | Oncology
227 St Paul Place, 4th Floor, 
Baltimore, MD 
Experienced in Familial Wilms Tumor 2
227 St Paul Place, 4th Floor, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Marvin Feldman is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Feldman is rated as an Experienced provider by MediFind in the treatment of Familial Wilms Tumor 2. His top areas of expertise are Anal Cancer, Laryngeal Cancer, Familial Colorectal Cancer, and Angiosarcoma.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MD
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

227 St Paul Place, 4th Floor, Baltimore, MD 21202

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas
Enrollment Status: Active_not_recruiting
Publish Date: December 29, 2025
Intervention Type: Drug, Other
Study Drugs: Capecitabine, Carboplatin, Cisplatin, Etoposide, Temozolomide
Study Phase: Phase 2
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2025
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2025
Intervention Type: Drug
Study Drugs: alpelisib, nab-paclitaxel
Study Phase: Phase 3
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drugs: Pazopanib, Pazopanib Hydrochloride, Sapanisertib
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

4 Total Publications

Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704.
Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer: Results of an Ancillary Analysis of NRG Oncology/RTOG 9704.
Journal: The oncologist
Published: July 24, 2019
Similar Doctors
Distinguished in Familial Wilms Tumor 2
Dr. Myo K. Min
Hematology Oncology | Hematology | Oncology
Distinguished in Familial Wilms Tumor 2
Dr. Myo K. Min
Hematology Oncology | Hematology | Oncology

Upper Chesapeake Hematology And Oncology Services, LLC

9114 Philadelphia Rd, Suite 208, 
Baltimore, MD 
 (8.5 miles away)
410-687-5300
Languages Spoken:
English, Burmese
See accepted insurances
Accepting New Patients
Offers Telehealth

Myo Min is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Min is rated as a Distinguished provider by MediFind in the treatment of Familial Wilms Tumor 2. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Colorectal Cancer, and Large-Cell Immunoblastic Lymphoma. Dr. Min is currently accepting new patients.

Distinguished in Familial Wilms Tumor 2
Dr. Jeanny B. Aragon-Ching
Oncology | Hematology | Hematology Oncology
Distinguished in Familial Wilms Tumor 2
Dr. Jeanny B. Aragon-Ching
Oncology | Hematology | Hematology Oncology

Inova Health Care Services

4320 Seminary Rd, 
Alexandria, VA 
 (41.7 miles away)
Languages Spoken:
English, Filipino
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeanny Aragon-Ching is an Oncologist and a Hematologist in Alexandria, Virginia. Dr. Aragon-Ching is rated as a Distinguished provider by MediFind in the treatment of Familial Wilms Tumor 2. Her top areas of expertise are Prostate Cancer, Urothelial Cancer, Bladder Cancer, Orchiectomy, and Prostatectomy. Dr. Aragon-Ching is currently accepting new patients.

Distinguished in Familial Wilms Tumor 2
Dr. Heather D. Mannuel
Oncology | Hematology
Distinguished in Familial Wilms Tumor 2
Dr. Heather D. Mannuel
Oncology | Hematology

University Of Maryland Oncology Associates PA

22 S Green St, 
Baltimore, MD 
 (0.7 miles away)
410-328-1230
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Heather Mannuel is an Oncologist and a Hematologist in Baltimore, Maryland. Dr. Mannuel is rated as a Distinguished provider by MediFind in the treatment of Familial Wilms Tumor 2. Her top areas of expertise are Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Prostate Cancer, and Renal Cell Carcinoma (RCC). Dr. Mannuel is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Feldman's expertise for a condition
ConditionClose
    View All 34 Advanced Conditions
    View All 111 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile